CMTM5-v1 is found to inhibit prostate cancer (PCa) cells through the EGFR signaling pathway, and the loss of CMTM5 may be involved in the occurrence and development of PCa caused by deregulated EGFR. The gene discussed is CMTM5; the disease is posterior cortical atrophy.